Ganglioside GD2 (Disialoganglioside GD2) is a tumor-associated antigen. Ganglioside GD2 shows limited expression in normal tissues but is overexpressed in multiple tumor types, and thus can serve as a target in cancer. Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action relies on enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on the tumor type^[1][2].

Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action involves enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on tumor type^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Nazha B, et al. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. Published 2020 Jul 7.  [Content Brief]

  [2]. Erber R, et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers (Basel). 2021;13(21):5577. Published 2021 Nov 8.  [Content Brief]